Short-term Adverse Events With BIC/FTC/TAF: Postmarketing Study

Bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF) was Food and Drug Administration approved in February 2018. The paucity of real-world data prompted this retrospective, observational evaluation of discontinuation rates, adverse effects, and virologic control. In a Southern US, predo...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayes, Edwin, Derrick, Caroline, Smalls, Danielle, Smith, Hilary, Kremer, Nicole, Weissman, Sharon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470466/
https://www.ncbi.nlm.nih.gov/pubmed/32908943
http://dx.doi.org/10.1093/ofid/ofaa285
_version_ 1783578594832809984
author Hayes, Edwin
Derrick, Caroline
Smalls, Danielle
Smith, Hilary
Kremer, Nicole
Weissman, Sharon
author_facet Hayes, Edwin
Derrick, Caroline
Smalls, Danielle
Smith, Hilary
Kremer, Nicole
Weissman, Sharon
author_sort Hayes, Edwin
collection PubMed
description Bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF) was Food and Drug Administration approved in February 2018. The paucity of real-world data prompted this retrospective, observational evaluation of discontinuation rates, adverse effects, and virologic control. In a Southern US, predominantly African American overweight population, we found optimal virologic control and low discontinuation rates, with 4% discontinuing BIC/FTC/TAF due to rash, low platelets, loss of appetite, and insomnia.
format Online
Article
Text
id pubmed-7470466
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-74704662020-09-08 Short-term Adverse Events With BIC/FTC/TAF: Postmarketing Study Hayes, Edwin Derrick, Caroline Smalls, Danielle Smith, Hilary Kremer, Nicole Weissman, Sharon Open Forum Infect Dis Brief Report Bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF) was Food and Drug Administration approved in February 2018. The paucity of real-world data prompted this retrospective, observational evaluation of discontinuation rates, adverse effects, and virologic control. In a Southern US, predominantly African American overweight population, we found optimal virologic control and low discontinuation rates, with 4% discontinuing BIC/FTC/TAF due to rash, low platelets, loss of appetite, and insomnia. Oxford University Press 2020-09-03 /pmc/articles/PMC7470466/ /pubmed/32908943 http://dx.doi.org/10.1093/ofid/ofaa285 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Hayes, Edwin
Derrick, Caroline
Smalls, Danielle
Smith, Hilary
Kremer, Nicole
Weissman, Sharon
Short-term Adverse Events With BIC/FTC/TAF: Postmarketing Study
title Short-term Adverse Events With BIC/FTC/TAF: Postmarketing Study
title_full Short-term Adverse Events With BIC/FTC/TAF: Postmarketing Study
title_fullStr Short-term Adverse Events With BIC/FTC/TAF: Postmarketing Study
title_full_unstemmed Short-term Adverse Events With BIC/FTC/TAF: Postmarketing Study
title_short Short-term Adverse Events With BIC/FTC/TAF: Postmarketing Study
title_sort short-term adverse events with bic/ftc/taf: postmarketing study
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470466/
https://www.ncbi.nlm.nih.gov/pubmed/32908943
http://dx.doi.org/10.1093/ofid/ofaa285
work_keys_str_mv AT hayesedwin shorttermadverseeventswithbicftctafpostmarketingstudy
AT derrickcaroline shorttermadverseeventswithbicftctafpostmarketingstudy
AT smallsdanielle shorttermadverseeventswithbicftctafpostmarketingstudy
AT smithhilary shorttermadverseeventswithbicftctafpostmarketingstudy
AT kremernicole shorttermadverseeventswithbicftctafpostmarketingstudy
AT weissmansharon shorttermadverseeventswithbicftctafpostmarketingstudy

Ejemplares similares